Piper Sandler Adjusts Price Target on AbbVie to $196 From $190
HC Wainwright Adjusts Price Target on United Therapeutics to $400 From $300, Maintains Buy Rating
Cantor Fitzgerald Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $885
H.C. Wainwright Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $400
United Therapeutics Analyst Ratings
Eli Lilly and Co Analyst Ratings
Wolfe Research Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,117
Wolfe Research Adjusts Eli Lilly's Price Target to $1,117 From $909
Buy Rating Affirmed: Sangamo's Hemophilia A Gene Therapy Poised for Success With Pfizer Partnership
Daiwa Securities Adjusts Price Target on Abbott Laboratories to $120 From $125
Stifel Maintains Geron(GERN.US) With Buy Rating, Maintains Target Price $7
Stifel Nicolaus Reaffirms Their Buy Rating on Geron (GERN)
Goldman Sachs Maintains Geron(GERN.US) With Buy Rating
Goldman Sachs Keeps Their Buy Rating on Geron (GERN)
Regeneron Pharma Price Target Raised to $1200.00/Share From $1030.00 by TD Cowen
Regeneron Pharmaceuticals Analyst Ratings
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,200
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $360
Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $190
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,166